1. Medtech Insight
  2. >>Business

VC Deals Analysis: Where Art Thou, Big Deals?

 
• By Tina Tan

July's batch of medtech venture financing rounds was a classic example of quantity trumping quality. While deal volume was twice as high as June's, there was a notable absence of meaty transactions.

SC1607_USDollarBillBandage_1200x675

[Editors' note: For more details about VC deals in 2016 and previous years, go to Medtech Insight's VC deal tracker: https://medtech.pharmamedtechbi.com/datasets/vc-funding.]

At first glance, July looked like an end to a recent lull in medtech venture financing activity as deal volume...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.